Energenesis Biomedical Co's ROE % for the quarter that ended in Dec. 2025 was -27.42%. Energenesis Biomedical Co's PB Ratio for the quarter that ended in Dec. 2025 was 4.22.
Energenesis Biomedical Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -6.50%.
Energenesis Biomedical Co ROE % Adjusted to Book Value Related Terms
Energenesis Biomedical Co ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Energenesis Biomedical Co's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Energenesis Biomedical Co ROE % Adjusted to Book Value Chart
TPE:6657 vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Energenesis Biomedical Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Energenesis Biomedical Co ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Energenesis Biomedical Co's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Energenesis Biomedical Co's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -6.50% mean?
Energenesis Biomedical Co (TPE:6657) has a ROE % Adjusted to Book Value of -6.50% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Energenesis Biomedical Co and its competitors.
Is Energenesis Biomedical Co's ROE % Adjusted to Book Value too high?
Energenesis Biomedical Co's current ROE % Adjusted to Book Value is -6.50%. Overall, Energenesis Biomedical Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Energenesis Biomedical Co's ROE % Adjusted to Book Value compare to VRTX and REGN?
Energenesis Biomedical Co's ROE % Adjusted to Book Value of -6.50% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Energenesis Biomedical Co and its competitors. Energenesis Biomedical Co's current ROE % Adjusted to Book Value is -6.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Energenesis Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Energenesis Biomedical Co (TPE:6657) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$51.36, compared to a current price of NT$37.15 — trading 27.7% below its estimated fair value. The current ROE % Adjusted to Book Value is -6.50%. Energenesis Biomedical Co's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Energenesis Biomedical Co (TPE:6657), the current ROE % Adjusted to Book Value is -6.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Energenesis Biomedical Co (TPE:6657) Overvalued in 2026?
Based on GuruFocus' analysis, Energenesis Biomedical Co stock appears to be undervalued.
The current stock price of NT$37.15 is trading 27.7% below its estimated GF Value™ of NT$51.36.
GuruFocus considers Energenesis Biomedical Co to be Modestly Undervalued.
Key valuation signals for TPE:6657:
ROE % Adjusted to Book Value: -6.50%
GF Value™: NT$51.36 vs. price of NT$37.15 (27.7% below fair value)
No single metric tells the full story. See the TPE:6657 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Energenesis Biomedical Co Ltd is a biomedicine company. The company is engaged in businesses related to biological experimentation and analysis, as well as new drugs development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. The product pipeline of the company consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream,F708, Asthama treatment, and others.
63GF Score
Get the complete analysis for TPE:6657
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6657 has been successfully added to your 
